Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA schedules ob/gyn panel

This article was originally published in The Gray Sheet

Executive Summary

Female Health's PMA for the FC2 second generation female condom will go before FDA's Obstetrics and Gynecology Devices advisory panel May 16, the agency announces March 27 in the Federal Register. The firm's first-generation FC is the only product for women approved by FDA that provides dual protection against unintended pregnancy and sexually transmitted diseases, according to Female Health. The second-generation device is made of nitrile while the FC is made of polyurethane
Advertisement

Related Content

OB/GYN panel meeting
Advertisement
UsernamePublicRestriction

Register

MT025943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel